Study to Compare the Pharmacokinetics of AC 1202 and Two Doses of AC-SD-01 on Ketone Body Production

• Sponsor: Cerecin (Industry)
• Overall Status: Completed
• CT.gov ID: NCT03063645
• Collaborator: Celerion (Industry)
• Enrollment: 17
• Location: 1
• Arms: 3
• Actual Duration (Months): 1.8
• Patients Per Site Per Month: 9.4

Study Details

Study Description

Brief Summary

To compare serum ketone body (i.e., total ketones, β hydroxybutyrate, and estimate of acetoacetate) levels after single dose administration of AC-1202 and 2 doses of AC-SD-01.

Condition or Disease	Intervention/Treatment	Phase
Healthy	Drug: AC-1202; Drug: AC-SD-01 (50 g); Drug: AC-SD-01 (75 g)	Phase 1

Study Design

• Study Type: Interventional
• Actual Enrollment: 17 participants
• Allocation: Randomized
• Intervention Model: Crossover Assignment
• Intervention Model Description: 16 healthy subjects enrolled, each subject will receive 1 dose of each treatment, with a 2 day washout in between.16 healthy subjects enrolled, each subject will receive 1 dose of each treatment, with a 2 day washout in between.
• Masking: None (Open Label)
• Primary Purpose: Other
• Official Title: A Phase 1, Pilot, Single-Dose, 3-Way Crossover Study to Compare the Pharmacokinetics of AC 1202 and Two Doses of AC-SD-01 on Ketone Body Production
• Actual Study Start Date: Mar 11, 2017
• Actual Primary Completion Date: Apr 7, 2017
• Actual Study Completion Date: May 5, 2017

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Group ABC AC-1202, AC-SD-01 (50g), AC-SD-01 (75g)	Drug: AC-1202; 60 g AC-1202 mixed in 240 mL of water at Hour 0 Day 1; Drug: AC-SD-01 (50 g); 50 g AC-SD-01 mixed in 240 mL of water at Hour 0 Day 1; Drug: AC-SD-01 (75 g); 75 g AC-SD-01 mixed in 240 mL of water at Hour 0 Day 1
Experimental: Group BCA AC-SD-01 (50g), AC-SD-01 (75g), AC-1202	Drug: AC-1202; 60 g AC-1202 mixed in 240 mL of water at Hour 0 Day 1; Drug: AC-SD-01 (50 g); 50 g AC-SD-01 mixed in 240 mL of water at Hour 0 Day 1; Drug: AC-SD-01 (75 g); 75 g AC-SD-01 mixed in 240 mL of water at Hour 0 Day 1
Experimental: Group CAB AC-SD-01 (75g), AC-1202, AC-SD-01 (50g)	Drug: AC-1202; 60 g AC-1202 mixed in 240 mL of water at Hour 0 Day 1; Drug: AC-SD-01 (50 g); 50 g AC-SD-01 mixed in 240 mL of water at Hour 0 Day 1; Drug: AC-SD-01 (75 g); 75 g AC-SD-01 mixed in 240 mL of water at Hour 0 Day 1

Outcome Measures

Primary Outcome Measures

1. total ketones AUC0-t [0-24 hrs]

   The area under the concentration-time curve, from time 0 to the last observed non-zero concentration, as calculated by the linear trapezoidal method.

2. total ketones AUC0-inf [0-24 hrs]

   The area under the concentration-time curve from time 0 extrapolated to infinity. AUC0-inf is calculated as the sum of AUC0-t plus the ratio of the last measurable serum concentration to the elimination rate constant.

3. total ketones AUC%extap [0-24 hrs]

   Percent of AUC0-inf extrapolated, represented as (1 - AUC0-t/AUC0-inf)*100

4. total ketones Cmax [0-24 hrs]

   Maximum observed concentration

5. total ketones Kel [0-24 hrs]

   Apparent first-order terminal elimination rate constant calculated from a semi-log plot of the serum concentration versus time curve. The parameter will be calculated by linear least-squares regression analysis using the maximum number of points in the terminal log-linear phase (e.g., there or more non-zero serum concentrations)

6. total ketones T 1/2 [0-24 hrs]

   Apparent first-order terminal elimination half-life will be calculated as 0.693/Kel

7. total ketones Tmax [0-24 hrs]

   Time to reach Cmax. If the value occurs at more than one time points, Tmax is defined as the first time point with this value

8. β hydroxybutyrate AUC0-t [0-24 hrs]

   The area under the concentration-time curve, from time 0 to the last observed non-zero concentration, as calculated by the linear trapezoidal method.

9. β hydroxybutyrate AUC0-inf [0-24 hrs]

   The area under the concentration time curve from time 0 extrapolated to infinity. AUC0inf is calculated as the sum of AUC0t plus the ratio of the last measurable serum concentration to the elimination rate constant.

10. β hydroxybutyrate AUC%extap [0-24 hrs]

    Percent of AUC0-inf extrapolated, represented as (1 AUC0t/ AUC0inf)* 100

11. β hydroxybutyrate Cmax [0-24 hrs]

    Maximum observed concentration

12. β hydroxybutyrate Kel [0-24 hrs]

    Apparent first-order terminal elimination rate constant calculated from a semi-log plot of the serum concentration versus time curve. The parameter will be calculated by linear least-squares regression analysis using the maximum number of points in the terminal log-linear phase (e.g., three or more nonzero serum concentrations)

13. β hydroxybutyrate T 1/2 [0-24 hrs]

    Apparent first-order terminal elimination half-life will be calculated as 0.693/Kel

14. β hydroxybutyrate Tmax [0-24 hrs]

    Time to reach Cmax. If the value occurs at more than one time point, Tmax is defined as the first time point with this value

15. estimate of acetoacetate AUC0-t [0-24 hrs]

    Difference between total ketones AUC0-t and total β hydroxybutyrate AUC0-t

16. estimate of acetoacetate AUC0-inf [0-24 hrs]

    Difference between total ketones AUC0-inf and total β hydroxybutyrate AUC0-inf

17. estimate of acetoacetate AUC%extap [0-24 hrs]

    Difference between total ketones AUC%extap and total β hydroxybutyrate AUC%extap

18. estimate of acetoacetate Cmax [0-24 hrs]

    Difference between total ketones Cmax and total β hydroxybutyrate Cmax

19. estimate of acetoacetate Kel [0-24 hrs]

    Difference between total ketones Kel and total β hydroxybutyrate Kel

20. estimate of acetoacetate T 1/2 [0-24 hrs]

    Difference between total ketones T 1/2 and total β hydroxybutyrate T 1/2

21. estimate of acetoacetate Tmax [0-24 hrs]

    Difference between total ketones Tmax and total β hydroxybutyrate Tmax

Eligibility Criteria

Criteria

• Ages Eligible for Study: 19 Years to 55 Years
• Sexes Eligible for Study: Male
• Accepts Healthy Volunteers: Yes

Inclusion Criteria:

1. Healthy, adult, male 19-55 years of age, inclusive, at screening.

2. Continuous non smoker who has not used nicotine containing products for at least 3 months prior to Day -1 of Period 1 and throughout the study.

3. Body mass index (BMI) ≥ 20.0 and ≤ 30.0 kg/m2 at screening.

4. Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vital signs or ECGs, as deemed by the PI or designee. At screening, subjects must have alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP) < the upper limit of normal and triglyceride levels must be < 250 mg/dL.

5. A non vasectomized subject must agree to use a condom with spermicide or abstain from sexual intercourse during the study. (No restrictions are required for a vasectomized male provided his vasectomy has been performed 4 months or more prior to Day -1 of Period 1. A subject who has been vasectomized less than 4 months prior to Day -1 of Period 1 must follow the same restrictions as a non vasectomized male).

6. Understands the study procedures in the informed consent form (ICF), and be willing and able to comply with the protocol.

Exclusion Criteria:

1. Subject is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study.

2. History or presence of clinically significant medical or psychiatric condition or disease in the opinion of the PI or designee.

3. History of any illness that, in the opinion of the PI or designee, might confound the results of the study or poses an additional risk to the subject by their participation in the study.

4. History or presence of alcoholism or drug abuse within the past 2 years prior to Day -1 of Period 1.

5. History or presence of galactosemia or hypersensitivity or idiosyncratic reaction to the study drugs, related compounds, milk, palm or coconut oil, or soy.

6. History or presence of diverticular disease, ulcers, inflammatory bowel disease or recurrent diarrhea or gout.

7. Positive urine drug or alcohol results at screening or check in.

8. Positive results at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV).

9. Seated blood pressure is less than 90/40 mmHg or greater than 140/90 mmHg at screening.

10. Seated heart rate is lower than 40 bpm or higher than 99 bpm at screening.

11. QTcF interval is > 460 msec or subject has ECG findings deemed abnormal with clinical significance by the PI or designee at screening.

12. Estimated creatinine clearance ≤ 80 mL/min at screening.

13. Unable to refrain from or anticipates the use of any drug, including prescription and non prescription medications, herbal remedies, or vitamin supplements beginning 14 days prior to Day -1 of Period 1 and throughout the study. Acetaminophen (up to 2 g per 24 hour period) may be permitted during the study.

14. Has been on a diet incompatible with the on study diet, in the opinion of the PI or designee, within the 28 days prior to Day -1 of Period 1 and throughout the study.

15. Is lactose intolerant.

16. Is unable to complete the meal prior to Hour 0 on Day -1 of Period 1 and prior to dosing on Day 1 of Period 1.

17. Subject consumed grapefruit or Seville oranges within 14 days prior to Day -1 of Period 1.

18. Donation of blood or significant blood loss within 56 days prior to Day -1 of Period

20. Plasma donation within 7 days prior to Day -1 of Period 1.

21. Participation in another clinical study within 28 days prior to Day -1 of Period 1. The 28 day window will be derived from the date of the last blood collection or dosing, whichever is later, in the previous study to Day -1 of Period 1 of the current study.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Celerion	Lincoln	Nebraska	United States	68502

Sponsors and Collaborators

• Cerecin
• Celerion

Investigators

• Principal Investigator: Charles Tomek, MD, Celerion

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Cerecin
• ClinicalTrials.gov Identifier: NCT03063645
• Other Study ID Numbers: AC-17-014_BE
• First Posted: Feb 24, 2017
• Last Update Posted: Jun 27, 2017
• Last Verified: Jun 1, 2017

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Keywords provided by Cerecin: Healthy volunteer; AC-1202; AC-SD-01; Pharacokinetic; ketone body

Study Results

No Results Posted as of Jun 27, 2017